DURHAM, NC and LONDON — November 24, 2025 — Leads & Copy — Polarean Imaging plc (AIM: POLX) has signed an exclusive distribution agreement with DK Healthcare Co., Ltd. for its Xenon MRI platform in South Korea.
The agreement marks Polarean’s second international distribution partnership, enhancing the company’s commercial presence in the Asia-Pacific region. Polarean is strategically positioning its Xenon MRI platform to enter South Korea’s advanced medical imaging market. The company will collaborate with DK Healthcare to secure regulatory clearances before launching in South Korea.
DK Healthcare, established in Seoul in 1986, specializes in diagnostic radiology systems and imaging technologies. It is an affiliate of DK, and known for its partnerships with global medical device manufacturers, providing imaging solutions and technical support.
Polarean’s CEO, Christopher von Jako, Ph.D., expressed delight in partnering with DK Healthcare, stating that South Korea’s focus on early detection and precision medicine makes it an ideal growth market. The agreement supports Polarean’s international expansion strategy, complementing domestic adoption efforts in the U.S.
Joonhyuk Lee, CEO of DK Healthcare, said that the company is excited to introduce Polarean’s Xenon MRI technology to leading Korean hospitals and imaging centers. Lee added that the platform enables visualization of ventilation and gas-exchange, a new dimension in lung function assessment that was previously impossible with conventional imaging. DK Healthcare believes that Xenon MRI will play a crucial role in transforming respiratory care in South Korea, enhancing early detection and improving outcomes for patients with lung cancer and COPD.
Polarean is a revenue-generating medical imaging technology company focused on pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. Polarean strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW™, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercializing innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.
XENOVIEW IMPORTANT SAFETY INFORMATION
Indication: XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 6 years and older.
Limitations of Use: XENOVIEW has not been evaluated for use with lung perfusion imaging.
CONTRAINDICATIONS: None.
Warnings and Precautions:
Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.
Adverse Reactions: Oropharyngeal pain, headache, and dizziness, blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria.
Chuck Osborne, Chief Financial Officer, +1 (919) 206-7900, ext. 117, cosborne@polarean.com
Anna Dunphy / Phillip Marriage, +44 (0)20 7933 8780, polarean@wallbrookpr.com
Alexis Opp, +1 (919) 206-7900, ext. 145, aopp@polarean.com
General inquiries: info@polarean.com
Source: Polarean Imaging plc
